Journal
NATURE
Volume 573, Issue 7775, Pages 595-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41586-019-1577-5
Keywords
-
Categories
Funding
- American Cancer Society Postdoctoral Fellowship [126337-PF-14-066-01-TBE]
- T32 training grant from the NICHD [T32HD060600]
- MSKCC Translational Research Oncology Training Fellowship [NIH T32-CA160001]
- NIH [NIH R00CA191021]
- American Association for Cancer Research/Pancreatic Cancer Action Network Pathway to Leadership Award
- William C. and Joyce C. O'Neil Charitable Trust
- Memorial Sloan Kettering Single Cell Sequencing Initiative
- Damon Runyon Cancer Research Foundation [DFS-23-17]
- Lustgarten Research Investigator Award
- National Cancer Institute
- Emerson Collective
- Starr Cancer Consortium [I11-039, I12-0051]
- Concern Foundation
- Anna Fuller Fund
- Memorial Sloan Kettering Cancer Center Support Grant [P30 CA008748]
Ask authors/readers for more resources
The tumour suppressor TP53 is mutated in the majority of human cancers, and in over 70% of pancreatic ductal adenocarcinoma (PDAC)(1,2). Wild-type p53 accumulates in response to cellular stress, and regulates gene expression to alter cell fate and prevent tumour development(2). Wild-type p53 is also known to modulate cellular metabolic pathways(3), although p53-dependent metabolic alterations that constrain cancer progression remain poorly understood. Here we find that p53 remodels cancer-cell metabolism to enforce changes in chromatin and gene expression that favour a premalignant cell fate. Restoring p53 function in cancer cells derived from KRAS-mutant mouse models of PDAC leads to the accumulation of alpha-ketoglutarate (alpha KG, also known as 2-oxoglutarate), a metabolite that also serves as an obligate substrate for a subset of chromatin-modifying enzymes. p53 induces transcriptional programs that are characteristic of premalignant differentiation, and this effect can be partially recapitulated by the addition of cell-permeable alpha KG. Increased levels of the alpha KG-dependent chromatin modification 5-hydroxymethylcytosine (5hmC) accompany the tumour-cell differentiation that is triggered by p53, whereas decreased 5hmC characterizes the transition from premalignant to de-differentiated malignant lesions that is associated with mutations in Trp53. Enforcing the accumulation of alpha KG in p53-deficient PDAC cells through the inhibition of oxoglutarate dehydrogenase-an enzyme of the tricarboxylic acid cycle-specifically results in increased 5hmC, tumour-cell differentiation and decreased tumour-cell fitness. Conversely, increasing the intracellular levels of succinate (a competitive inhibitor of alpha KG-dependent dioxygenases) blunts p53-driven tumour suppression. These data suggest that alpha KG is an effector of p53-mediated tumour suppression, and that the accumulation of alpha KG in p53-deficient tumours can drive tumour-cell differentiation and antagonize malignant progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available